KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Deferred Taxes (2016 - 2025)

Historic Deferred Taxes for Quest Diagnostics (DGX) over the last 17 years, with Q3 2025 value amounting to $110.0 million.

  • Quest Diagnostics' Deferred Taxes rose 63333.33% to $110.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $152.0 million, marking a year-over-year increase of 59032.26%. This contributed to the annual value of $13.0 million for FY2024, which is 12653.06% up from last year.
  • As of Q3 2025, Quest Diagnostics' Deferred Taxes stood at $110.0 million, which was up 63333.33% from $1.0 million recorded in Q2 2025.
  • Over the past 5 years, Quest Diagnostics' Deferred Taxes peaked at $110.0 million during Q3 2025, and registered a low of -$72.0 million during Q2 2021.
  • Over the past 5 years, Quest Diagnostics' median Deferred Taxes value was -$4.0 million (recorded in 2023), while the average stood at $1.4 million.
  • As far as peak fluctuations go, Quest Diagnostics' Deferred Taxes crashed by 90000.0% in 2021, and later skyrocketed by 315000.0% in 2022.
  • Quest Diagnostics' Deferred Taxes (Quarter) stood at $30.0 million in 2021, then tumbled by 246.67% to -$44.0 million in 2022, then soared by 77.27% to -$10.0 million in 2023, then surged by 440.0% to $34.0 million in 2024, then surged by 223.53% to $110.0 million in 2025.
  • Its last three reported values are $110.0 million in Q3 2025, $1.0 million for Q2 2025, and $7.0 million during Q1 2025.